IDAHO DEPARTMENT OF HEALTH & WELFARE

DIVISION OF PUBLIC HEALTH

BUREAU OF LABORATORIES

www.statelab.idaho.gov

IDAHO SENTINEL LABORATORY NETWORK LAB UPDATE

April 20, 2016

ZIKA VIRUS TESTING CAPABILITIES AT IDAHO BUREAU OF LABORATORIES

The Idaho Bureau of Laboratories (IBL) has recently been authorized to offer the Trioplex PCR (molecular) test for the identification of Zika, dengue, and chikungunya virus. Providers are advised to consult the current Idaho Public Health Guidance for Zika Virus Testing guidance located at http://www.epi.idaho.gov prior to submitting samples to IBL. If a patient meets the listed indications for testing, please:

- Notify Public Health District or state epidemiologists using the contact information in the guidance.
- Call 208-334-0589 to notify IBL when the shipment may arrive.
- Collect and package at least 0.5 mL of serum (not whole blood). If cerebrospinal fluid (CSF) (1.0 mL) is submitted, it must be accompanied by a serum specimen. Keep the specimen cold (do not freeze). Send in an insulated container with ice packs.
- Complete CDC form 50.34 for Idaho linked from the IBL Clinical Microbiology webpage. Onset date, symptoms, pregnancy status, and travel history and dates must be included. See Instructions for CDC Form 50.34 for Zika linked from http://www.epi.idaho.gov and the IBL Clinical Microbiology webpage. Samples with incomplete information on submittal forms will not be shipped for testing.
- Send the sample with completed CDC form 50.34 for Idaho to IBL (Attention: Virology Laboratory), as a Category B package.
- If sample type and onset date are appropriate, IBL will perform PCR testing on the sample and may forward the sample to CDC for serology (e.g., IgM antibody, PRNT) testing. There is currently no charge for testing by CDC or IBL. Final results are expected to be reported **to the submitter listed on the submittal form** within 4 weeks after specimen receipt at CDC. PCR results by IBL will be reported with a shorter turnaround time.

IBL is available to provide result interpretation to providers should there be any questions about the PCR or serology testing performed at CDC. Please refer to the Idaho Public Health Guidance for Zika Virus Testing document for contact information.

The current tiered algorithm for testing of symptomatic, suspected cases of chikungunya, dengue, or Zika virus infection is shown below and available online.



- [1] **Due to extensive cross-reactivity in flavivirus serological assays, for samples collected <7 days post illness onset, molecular detection should be performed first.**
- [2] Perform if sample ≥4 days after symptom onset
- [3] Extensive cross-reactivity would be expected in samples from DENV/ZIKV circulation areas. A positive IgM assay with either antigen should be confirmed by using PRNT against both ZIKV and DENV as well as any other flavivirus (eg. SLEV, ZIKV, WNV, etc.) that might be found in that geographic area (including travel areas).
- [4] PRNT should include any flavivirus (eg. SLEV, ZIKV, WNV, etc.) that might be found in that geographic area (including travel areas).

Message Categories

Lab Alert: conveys the highest level of importance; warrants immediate action or attention.

Lab Advisory: important information for a specific incident or situation; may not require immediate action.

Lab Update: updated information regarding an incident or situation; unlikely to require immediate action.